Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Prana Biotechnology — Shareholder Meeting (November 2018)
10 slides from Alterity Therapeutics's shareholder meeting presentation, Nov 15, 2018
Slide 1: Clinical Development Update
Clinical Development Update David Stamler, M.D. Annual General Meeting 16 November 2018
Slide 2: Highlights
Highlights 2 NOVEL DRUG CANDIDATE: PBT434 ▪ Targets key proteins implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism ▪ Prevents accumulation and aggregation of α - synuclein ▪ Phase 1 study in healthy volunteers ongoing STRONG RESEARCH AND DEVELOPMENT ▪ Innovative discov
Slide 3: U.S.-based clinical team with strong drug development experience and FDA approvals
U.S. - based clinical team with strong drug development experience and FDA approvals David Stamler, M.D. Chief Medical Officer & Senior VP, Clinical Development Previously Senior Director, Teva Pharmaceuticals. At Teva, l ed non - clinical development of several neuroscience programs . As Executive
Slide 4: PBT434 - Strong Development Rationale
PBT434 - Strong Development Rationale ● Alpha ( α) - synuclein is an intracellular protein critical for neurotransmission ● Alpha - synulein accumulates and aggregates in many neurodegenerative diseases, implicated in pathology ● PBT434 blocks α - synuclein accumulation and aggregation, preserves ne
Slide 5: Alpha-Synuclein – An Established Disease Target
Alpha - Synuclein – An Established Disease Target Strong Genetic and Pathological Link to Disease 5 https://www.michaeljfox.org/research/priority - area - detail.php?alpha - synuclein We conclude that alpha - synuclein remains one of the most compelling therapeutic targets for Parkinson's disease, a
Slide 6: Prana's Phase 1 study of PBT434
Prana’s Phase 1 study of PBT434 • Single and multiple ascending dose study • Healthy adult and elderly volunteers • Goals include assessing the safety, tolerability and pharmacokinetics of PBT434 • Commenced in June ’18 at Nucleus Network in Melbourne • Several single dose cohorts completed • Multip
Slide 7: Brain Iron Increased in Parkinson's Disease Patients
Brain Iron Increased in Parkinson’s Disease Patients Specialised MRI Technique (QSM) to Non - invasively Quantify Brain Iron (PD Patient) nmol iron/g of human brain nmol iron/g of human brain Dexter. Brain.1991;114 Langkammer. PLoS ONE 11(9): e0162460. 2016 7 And In Multiple System Atrophy Patients
Slide 8: Multiple System Atrophy
Multiple System Atrophy A form of Atypical Parkinsonism • Rapidly progressive neurodegenerative disorder leading to severe disability and impairment in quality of life • Sporadic, typically presents in 50s to 60s • Orphan Indication: Prevalence ~ 5 per 100,000 in the U.S. • Characterized by a variab
Slide 9: PBT434 Reduces Alpha-synuclein and Glial Cell Inclusions, Preserves Neurons
PBT434 Reduces Alpha - synuclein and Glial Cell Inclusions, Preserves Neurons and Improves Motor Function Transgenic Mouse Model (PLP) - α - SYN of MSA 9 Alpha - Synuclein Treatment: Randomly allocated, 4 months, 30 mg/kg/day or Vehicle Data presented are for animals at 16 mo age; substantia nigra
Slide 10: Summary
Summary • PBT434 targets α - synuclein, a biologically important protein implicated in neurodegenerative diseases • Iron is increased in the brain of patients with target diseases • PBT434 restores iron balance and blocks the accumulation and aggregation of this protein • PBT434 has shown clear effi
Prana Biotechnology — Shareholder Meeting (November 2018) on 6ix